Robocath is a medtech which designs, develops and commercializes robotic solutions to treat cardiovascular diseases.
Robocath works closely with healthcare professionals to develop robotic solutions for treating vascular diseases such as heart attack and stroke.
Robocath was founded in 2009 by Philippe Bencteux. The company is headquartered in Rouen, Normandie, France.
Robocath has developed R-One™, the first european robotic-assisted solution for PCI. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. It is designed to operate with precision and perform specific movements creating better interventional conditions.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.
Robocath is backed by GO CAPITAL, NCI, Normandie Participations, M Capital, Supernova Invest, Caisse d’épargne, BNP Paribas, Crédit Agricole), Bpifrance and others. The company raised €40M ($43M) in a Series C round on Apr 29, 2020. This brings Robocath's total funding to €51.4M ($55.8M) to date.